Cargando…

Neutrophils: Musketeers against immunotherapy

Neutrophils, the most copious leukocytes in human blood, play a critical role in tumorigenesis, cancer progression, and immune suppression. Recently, neutrophils have attracted the attention of researchers, immunologists, and oncologists because of their potential role in orchestrating immune evasio...

Descripción completa

Detalles Bibliográficos
Autores principales: Zahid, Kashif Rafiq, Raza, Umar, Tumbath, Soumya, Jiang, Lingxiang, Xu, Wenjuan, Huang, Xiumei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9453237/
https://www.ncbi.nlm.nih.gov/pubmed/36091114
http://dx.doi.org/10.3389/fonc.2022.975981
_version_ 1784785098087858176
author Zahid, Kashif Rafiq
Raza, Umar
Tumbath, Soumya
Jiang, Lingxiang
Xu, Wenjuan
Huang, Xiumei
author_facet Zahid, Kashif Rafiq
Raza, Umar
Tumbath, Soumya
Jiang, Lingxiang
Xu, Wenjuan
Huang, Xiumei
author_sort Zahid, Kashif Rafiq
collection PubMed
description Neutrophils, the most copious leukocytes in human blood, play a critical role in tumorigenesis, cancer progression, and immune suppression. Recently, neutrophils have attracted the attention of researchers, immunologists, and oncologists because of their potential role in orchestrating immune evasion in human diseases including cancer, which has led to a hot debate redefining the contribution of neutrophils in tumor progression and immunity. To make this debate fruitful, this review seeks to provide a recent update about the contribution of neutrophils in immune suppression and tumor progression. Here, we first described the molecular pathways through which neutrophils aid in cancer progression and orchestrate immune suppression/evasion. Later, we summarized the underlying molecular mechanisms of neutrophil-mediated therapy resistance and highlighted various approaches through which neutrophil antagonism may heighten the efficacy of the immune checkpoint blockade therapy. Finally, we have highlighted several unsolved questions and hope that answering these questions will provide a new avenue toward immunotherapy revolution.
format Online
Article
Text
id pubmed-9453237
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94532372022-09-09 Neutrophils: Musketeers against immunotherapy Zahid, Kashif Rafiq Raza, Umar Tumbath, Soumya Jiang, Lingxiang Xu, Wenjuan Huang, Xiumei Front Oncol Oncology Neutrophils, the most copious leukocytes in human blood, play a critical role in tumorigenesis, cancer progression, and immune suppression. Recently, neutrophils have attracted the attention of researchers, immunologists, and oncologists because of their potential role in orchestrating immune evasion in human diseases including cancer, which has led to a hot debate redefining the contribution of neutrophils in tumor progression and immunity. To make this debate fruitful, this review seeks to provide a recent update about the contribution of neutrophils in immune suppression and tumor progression. Here, we first described the molecular pathways through which neutrophils aid in cancer progression and orchestrate immune suppression/evasion. Later, we summarized the underlying molecular mechanisms of neutrophil-mediated therapy resistance and highlighted various approaches through which neutrophil antagonism may heighten the efficacy of the immune checkpoint blockade therapy. Finally, we have highlighted several unsolved questions and hope that answering these questions will provide a new avenue toward immunotherapy revolution. Frontiers Media S.A. 2022-08-25 /pmc/articles/PMC9453237/ /pubmed/36091114 http://dx.doi.org/10.3389/fonc.2022.975981 Text en Copyright © 2022 Zahid, Raza, Tumbath, Jiang, Xu and Huang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Zahid, Kashif Rafiq
Raza, Umar
Tumbath, Soumya
Jiang, Lingxiang
Xu, Wenjuan
Huang, Xiumei
Neutrophils: Musketeers against immunotherapy
title Neutrophils: Musketeers against immunotherapy
title_full Neutrophils: Musketeers against immunotherapy
title_fullStr Neutrophils: Musketeers against immunotherapy
title_full_unstemmed Neutrophils: Musketeers against immunotherapy
title_short Neutrophils: Musketeers against immunotherapy
title_sort neutrophils: musketeers against immunotherapy
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9453237/
https://www.ncbi.nlm.nih.gov/pubmed/36091114
http://dx.doi.org/10.3389/fonc.2022.975981
work_keys_str_mv AT zahidkashifrafiq neutrophilsmusketeersagainstimmunotherapy
AT razaumar neutrophilsmusketeersagainstimmunotherapy
AT tumbathsoumya neutrophilsmusketeersagainstimmunotherapy
AT jianglingxiang neutrophilsmusketeersagainstimmunotherapy
AT xuwenjuan neutrophilsmusketeersagainstimmunotherapy
AT huangxiumei neutrophilsmusketeersagainstimmunotherapy